Eli Lilly and Company
LLY.TO
Toronto Stock Exchange39.36
CAD
-0.13
- -
ISIN
CA28655A1066
CUSIP
28655A106
Return %
Stock
S&P500
1Y
0.72
25.65
3Y
0.72
70.81
5Y
0.72
77.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- David A. Ricks
- Full Time Employees
- 50,000
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- P.O. Box 73, Exchange Tower 130 King Street West, Suite 900 Indianapolis ON United States of America M5X 1B1
- IPO Date
- Dec 22, 2025
- Website
- lilly.ca
- Similar Companies
- Business
- Eli Lilly and Company is a global pharmaceutical company that develops, manufactures, and markets branded prescription medicines across multiple therapeutic areas, with a focus on diabetes and obesity, oncology, immunology, neuroscience, and cardiovascular health. The company operates through a diversified product portfolio that includes insulin analogs and other diabetes therapies, obesity treatments, oncology medicines, immunology biologics, and central nervous system agents, complemented by devices and delivery technologies where applicable. Lilly’s core products and services encompass pharmaceutical research and development, manufacturing, regulatory submissions, product commercialization, patient access programs, and collaboration partnerships to advance therapies from discovery through market launch. Founding year and headquarters - Founded in 1876; headquartered in Indianapolis, Indiana, United States. Latest major company changes - Forms strategic partnerships and collaborations to expand its pipeline and accelerate development of novel therapies, including alliances with biotechnology firms and academic partners to enhance immunology, oncology, and metabolic programs; these partnerships often include co-development and potential milestone-driven funding. - Engages in acquisitions and minority investments to broaden its therapeutic portfolio and capabilities, including strategic investments in gene therapy, biotechnology platforms, and platform technologies to support next-generation medicines. - Announces new product launches or label expansions for independently approved therapies and pipeline candidates, including obesity and diabetes treatments, immune-oncology assets, and neuroscience programs; these launches are often accompanied by expanded geographic approvals and payer negotiations. - Implements organizational and operational changes to strengthen commercial execution, manufacturing scalability, and early-phase research capabilities; recent years see reorganizations aimed at accelerating development timelines and improving cross-functional collaboration. Product portfolio and services in detail - Diabetes and metabolic diseases: insulins (including long-acting and rapid-acting formulations); GLP-1 receptor agonists and other metabolic therapies; comprehensive diabetes management solutions through branded medicines and supportive patient access programs. - Oncology: targeted therapies and immuno-oncology agents addressing solid tumors and hematologic malignancies; combination regimens and companion diagnostics to optimize patient selection and outcomes. - Immunology and inflammation: biologic therapies for autoimmune diseases and inflammatory conditions, including monoclonal antibodies and fusion proteins with expanding indications. - Neuroscience: treatments for mood disorders, neurodegenerative conditions, and related CNS indications, supported by ongoing research and development efforts. - Cardiovascular health: therapies targeting metabolic and cardiovascular disease pathways, with emphasis on improving long-term outcomes and chronic disease management. - Diabetes care ecosystem: patient-centric programs, payer and reimbursement support, and digital health/remote monitoring capabilities integrated with therapy access. - Research and development services: early discovery, preclinical development, translational science, and clinical development across therapeutic areas; regulatory strategy and global market access planning; in-house manufacturing and supply chain optimization for scalable production. Geographic operations and presence - Maintains a global footprint spanning North America, Europe, Asia-Pacific, Latin America, and other regions; commercial activities, manufacturing facilities, and regional partnerships support a broad international reach. - Headquarters located in the United States with regional offices, manufacturing sites, and distribution networks designed to serve diverse health systems and patient populations worldwide. Subsidiaries and corporate structure - Operates through a centralized corporate umbrella with multiple product-specific franchises and therapeutic area teams; maintains collaborations and minority stakes with partner companies to augment research and commercialization capabilities. - Relationships with contract manufacturing organizations and contract research organizations to support scalable production and clinical development programs. Target markets and customer base - Primary customers include healthcare professionals (physicians, specialists, nurses), health systems, pharmacies, and payers; patient access programs and affordability initiatives are integral to market strategy. - Secondary audiences include researchers, academic institutions, biotech partners, and government health entities that participate in clinical trials, regulatory processes, and health policy discussions. Notes - Descriptions reflect recent publicly reported activities in partnerships, pipeline expansions, and product development that have occurred over the last 1–2 years, consistent with the company’s ongoing strategy to broaden its therapeutic offerings and global reach.